Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
LRRK2 is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain.
our similar early study and recent confirming experiments using the same reagents reported by Sheng et al. failed to reproduce the phenotype of the loss of dopaminergic neurons, although the mRNA of LRRK2 was molecularly disrupted
results demonstrate that zLRRK2 is an ortholog of hLRRK2 and that the deletion of WD40 domain (show DCAF12L2 Antibodies) of zLRRK2 provides a disease model for PD
p21-activated kinase 6 (PAK6 (show PAK6 Antibodies)) as a novel interactor of leucine-rich repeat kinase 2 (LRRK2), a kinase involved in Parkinson's disease
none of the G2019S or R1441G/C/H mutations of LRRK2 were found in any of the 125 screened patients with Idiopathic REM (show REM1 Antibodies) Sleep Behavior disorder.
Most asymptomatic LRRK2 with possible surrogate markers of parkinson's disease such as abnormal dopamine transporter imaging-SPECT
Data show that cyclin-dependent kinase 5 (Cdk5 (show CDK5 Antibodies)) could phosphorylate the adjacent S1627 in the leucine-rich repeat kinase 2 (LRRK2) R1628P mutant.
Elevated ratio of phosphorylated LRRK2 to total LRRK2 in urine predicted parkinsonian phenotypes in male LRRK2 carriers.
The LRRK2-R1441C Parkinson disease-related mutation results in decreased GTPase (show RACGAP1 Antibodies) activity.
The results support a preferential association of LRRK2 variants with excessive pro-inflammatory responses in Leprosy.
Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression
findings suggest that the alteration of Notch (show NOTCH1 Antibodies) signaling in mature neurons is a component of PD etiology linked to LRRK2
This sttudy showed that the Novel LRRK2 mutations in Parkinsonism.
The data implicate gain of LRRK2 function in the pathogenesis of Parkinson disease
LRRK2 regulates lysosome size, number and function in primary astrocytes and results show that expression of Parkinson's disease associated LRRK2 variants results in enlarged lysosomes
Present results suggest that LRRK2 may play novel roles in both the immune system and the pathogenesis of various diseases.
In the substantia nigra of LRRK2 transgenic mice, mRNA of three genes that promote cell death was upregulated, while the mRNA expression of seven genes that contribute to neurogenesis/neuroprotection was downregulated.
G2019S mutation carrying LRRK2 microglia show retarded ADP-induced motility and delayed isolation of injury. LRRK2 knockdown microglia are highly motile compared with control cells. Lrrk2 phosphorylates and inhibits focal adhesion kinase.
The Lrrk2 (-/-) mice developed lower levels of experimental autoimmune uveitis, delayed type hypersensitivity responses and cytokine production by lymphocytes than did their WT controls.
Phosphorylation of p53 (show TP53 Antibodies) by LRRK2 induces p21(WAF1/CIP1 (show CDKN1A Antibodies)) expression and apoptosis.
The results indicate that LRRK2 kinase activity has an important role in the regulation of clathrin-mediated endocytosis of synaptic vesicles and subsequent neurotransmission at the synapse.
show that the LRRK2 sequence and expression patterns are conserved between pig and human
This gene is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat (LRR) domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane. Mutations in this gene have been associated with Parkinson disease-8.
leucine-rich repeat serine/threonine-protein kinase 2
, leucine-rich repeat kinase 2
, leucine-rich repeat serine/threonine-protein kinase 2-like
, augmented in rheumatoid arthritis 17